Viloxazine Extended-Release: A Review in Attention-Deficit/Hyperactivity Disorder in Adults
An extended-release once-daily oral capsule formulation of viloxazine (viloxazine ER; Qelbree^(®)), a norepinephrine reuptake inhibitor and serotonin receptor modulator, has been approved in the USA for the treatment of attention-deficit/hyperactivity…
Suggested reading